
AI PRAZOLAM TABLETS LISP IV 0.25 mg. 0.5 mg. 1 mg and 2 mg By only

DESCRIPTION

Alprazolam Tablets, USP contain alprazolam which is a triazolo analog of the 1,4 benzodiazepine class of central nervous system-active compounds. The chemical name of alprazolam is 8-Chloro-1-methyl-6-phenyl-4H-s-triazolo[4,3-α][1,4] benzodiazenine

The structural formula is



M.W. = 308.76

C1.H.CIN

Alprazolam is a white crystalline powder, which is soluble in methanol or ethanol but which has no appreciable solubility in water at physiological pH.

Each alprazolam tablet, for oral administration, contains 0.25, 0.5, 1 or 2 mg of alprazolan



Inactive ingredients: Colloidal silicon dioxide, docusate sodium, lactose monohydrate, magnesium stearate, microcrystalline cellulose, sodium benzoate and sodium starch glycolate. In addition, the 0.5 mg tablet contains FD&C Yellow No. 6 Aluminum Lake and the 1 mg tablet contains FD&C Blue No. 1 Aluminum Lake.

CLINICAL PHARMACOLOGY CNS agents of the 1,4 benzodiazepine class presumably exert their effects by binding at stereo specific one degrado miser, e obtecedidente olado precedente ante ante ante a conservativa en la conservativa de la conservativa Conservativa de la conserv

Ecliptive and the provided of the provided of

(range: 6.3-26.9 hours) in neatiny adults. The predominant metabolities are α-hydroxy-alprazolam and a benzophenone derived from alprazol The biological activity of α-hydroxy-alprazolam is approximately one-half that of alprazolam. benzophenone metabolite is essentially inactive. Plasma levels of these metabolites are extremely thus precluding precise pharmacokinetic description. However, their half-lives appear to be of the s order of magnitude as that of alprazolam. Alprazolam and its metabolites are excreted primarily in

The ability of alprazolam to induce human hepatic enzyme systems has not yet been determined. However, this is not a property of benzodiazepines in general. Further, alprazolam did not affect the prothrombio nr plasma warfani levels in mela volunteres administered sodium warfarin orally.

In vitro, alprazolam is bound (80 percent) to human serum protein.

In vtro, alprazolam is bound (80 percent) to human serum protein. Changes in the absorption, distribution, metabolism and excretion of benzodiazepines have been reported in a variety of disease states including alcoholism, impaired hepatic function and impaired renal function. Changes have also been demonstrated in geriatric patients. A mean half-life of alprazolam of 16.3 hours has been observed in healthy elderly subjects (range: 9.0-26.9 hours, n=16) compared to 11.0 hours (range: 6.3-15.8 hours, n=16) in healthy adult subjects. In patients with alcoholic liver disease the half-life of alprazolam ranged between 5.8 and 65.3 hours (mean: 19.7 hours, n=17) as compared to between 6.3 and 26.9 hours (mean=11.4 hours, n=17) in healthy subjects. In an obses group of subjects the half-life of alprazolam ranged between 9.3 and 40.4 hours; (mean=21.8 hours, (n=12) as compared to between 6.3 and 15.8 hours (mean=10.6 hours, n=12) in healthy subjects.

Because of its similarity to other benzodiazepines, it is assumed that alprazolam undergoes transplacental passage and that it is excreted in human milk.

۲

2H 8522818

TABLETS, USP

0.25 ma. 0.5 ma.

1 mg and 2 mg

Rx only

transplaceman passage and that it is excreted in numan mix. INDICATIONS AND USAGE Alprazolam tablets are indicated for the management of anxiety disorder (a condition corresponding most closely to the APA Diagnostic and Statistical Manual [DSM-II-R] diagnosis of generalized anxiety disorder) or the short-term relief of symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. Generalized anxiety disorder is characterized by unrealistic or excessive anxiety and worry fearorebanetic exprestion) about tho or more life circumstances, for a period of six months or longer.

Generalized anxiety disorder is characterized by unrealistic or excessive anxiety and worry (apprehensive expectation) about two or more life circumstances, for a period of six months or longer, during which the person has been bothered more days than not by these concerns. At least 6 of the following 18 symptoms are othen present in these patients: *Motor Tension* (trembing, Whiching, or feeling shaky, muscle tension, aches, or soreness; restlessness; easy fatigability). *Autonomic Hyperactivity* (shortness of breath or smothering sensations; papitations or accelerated heart rate; sweating, or cold clammy hands; dry mouth; dizziness or light-headedness; nausea, diarrhea, or other abdominal distress; flushes or chills; frequent unriation; trouble swallowing or 'ump in throat'). *Vigilance and Scanning* (feeling keyed up or on edge; exaggerated startle response; difficulty concentrating or mind going blank because of anxiety; trouble falling or staying aleep; rintability). These symptoms must not be secondary to another psychiatric disorder or caused by some organic factor.

Anxiety associated with depression is responsive to alprazolam tablets.

Alprazolam tablets are also indicated for the treatment of panic disorder, with or without agoraphobia Studies supporting this claim were conducted in patients whose diagnoses corresponded closely to the DSM-III-R criteria for panic disorder (see **CLINICAL STUDIES**).

DSM-III-R criteria for panic disorder (see CLINICAL STUDIES). Panic disorder is an illness characterized by recurrent panic attacks. The panic attacks, at least initially, are unexpected. Later in the course of this disturbance certain situations, e.g., driving a car or being in a crowded place, may become associated with having a panic attack. These panic attacks are not triggered by situations in which the person is the focus of others' attention (as in social phobia). The diagnosis requires four such attacks within a four week period, or one or more attacks followed by at least a month of persistent fear of having another attack. The panic attacks must be characterized by at least at our of the following symptoms: dyspnea or smothering sensations; dizziness, unsteady feelings, or faintness; applitations or tachycardia; trembing or shaking; sweating; choking; nausea or adbominal distress; depersonalization or derealization; paresthesias; hot flashes or chills; chest pain or discomfort; fear of dying; fear of going crazy or of doing someting; swenting; chost not be attributale to some known organic factors. Panic disorder is frequently associated with some symptoms of agoraphobia. Demonstrations of the effectiveness of alorazolam tablets the vestematic clinical study are limited to four

Demonstrations of the effectiveness of alprazolam tablets by systematic clinical study are limited to four Demonstrations of une entercharterises or appraction in aquets of systematic chinical study are immered to loar months duration for anxiety disorder and four to ten weeks duration for panic disorder, however, patients with panic disorder have been treated on an open basis for up to eight months without apparent loss of benefit. The physician should periodically reassess the usefulness of the drug for the individual patient

benefit. The physician should periodically reassess the usefurness or the orug on the municular patient. **CONTRAINDICATIONS** Alprazolam tablets are contraindicated in patients with known sensitivity to this drug or other benzodiazepines. Alprazolam tablets may be used in patients with open angle glaucoma who are receiving appropriate therapy, but is contraindicated in patients with acute narrow angle glaucoma. Alprazolam tablets are contraindicated with ketoconazole and itraconazole, since these medications significantly impair the oxidative metabolism mediated by cytochrome P450 3A (CYP 3A) (see WARNINGS and PRECAUTIONS-Drug Interactions).

WARNINGS

WARNINGS Dependence and withdrawal reactions, including seizures: Certain adverse clinical events, some life-threatening, are a direct consequence of physical dependence to alprazolam tablets. These include a spectrum of withdrawal symptoms; the most important is seizure (see DRUG ABUSE AND DEPENDENCE). Even after relatively short-term use at the doses recommended for the treatment of transient anxiety and anxiety disorder (i.e., 0.75 to 4 mg per day), there is some risk of dependence. Spontaneous reporting system data suggest that the risk of dependence and its severity appear to be greater in patients treated with doses greater than 4 mg/day and for long periods (more than 12 weeks). However, in a controlled postmarketing discontinuation study of panic disorder patients, the duration of treatment (three months compared to six months) had no effect on the ability of patients to taper to zero dose. In contrast, patients treated with doses of alprazolam tablets greater than 4 mg/day had more difficulty tapering to zero dose than those treated with less than 4 mg/day. The importance of dose and the risks of alprazolam tablets as a treatment for panic disorder:

The importance of dose and the risks of alorazolam tablets as a treatment for panic disorde The importance or dose and the risks or alprazolam tablets as a treatment for planic disorder: Because the management of planic disorder often requires the use of average daily doses of alprazolam tablets above 4 mg, the risk of dependence among panic disorder patients may be higher than that among those treated for less severe anxiety. Experience in randomized placebo-controlled discontinuation studies of patients with panic disorder showed a high rate of rebound and withdrawal symptoms in patients treated with alprazolam tablets compared to placebo treated patients. Relapse or return of illness was defined as a return of symptoms characteristic of panic disorder (primarily panic attacks) to levels approximately equal to those seen at baseline before active treatment was initiated. Rebound refers to a return of symptoms of panic disorder to a level substantially greater in frequency, or more severe in intensity than seen at baseline. Withdrawal symptoms were identified as those which were generally not characteristic of panic disorder and which occurred for the first time more frequently during discontinuation than at baseline.

In a controlled clinical trial in which 63 patients were randomized to alprazolam tablets and where In a controlled clinical trial in which 53 patients were randomized to alprazolam tablets and where withdrawal symptoms were specifically sought, the following were identified as symptoms of withdrawal heightened sensory perception, impaired concentration, dysosmia, clouded sensorium, paresthesias, muscle cramps, muscle twitch, diarrhea, blurred vision, appetite decrease and weight loss. Other symptoms, such as anxiety and insomnia, were frequently seen during discontinuation, but it could not be determined if they were due to return of illness, rebound or withdrawal.

In a larger database comprised of both controlled and uncontrolled studies in which 641 patients received alprazolam tablets, discontinuation-emergent symptoms which occurred at a rate of over 5% in patients treated with alprazolam tablets and a 1 a greater rate than the placebo treated group were as

DISCONTINUATION-EMERGENT_SYMPTOM INCIDENCE centage of 641 Alprazolam Tablet-Treated Panic Disorder Patients Reporting Events

Neurologic		Gastrointestinal	
Insomnia	29.5	Nausea/vomiting	
Light-headedness	19.3	Diarrhea	
Abnormal involuntary movement	17.3	Decreased salivation	
Headache	17.0		
Muscular twitching	6.9	Metabolic-Nutritional	
Impaired coordination	6.6	Weight loss	
Muscle tone disorders	5.9	Decreased appetite	
Weakness	5.8		
		Dermatological	
Psychiatric		Sweating	
Anxiety	19.2	-	
Fatigue and tiredness	18.4	Cardiovascular	
Irritability	10.5	Tachycardia	
Cognitive disorder	10.3		
Memory impairment	5.5	Special Senses	
Depression	5.1	Blurred vision	
Confusional state	5.0		

From the studies cited, it has not been determined whether these symptoms are clearly related to the dose and duration of therapy with alprazolam tablets in patients with panic disorder.

In two controlled trials of six to eight weeks duration where the ability of patients to discontinue medication was measured, 71%-93% of alprazolam tablet-treated patients tapered completely of therapy compared to 89%-96% of placebo treated patients. In a controlled postmarke ation study of panic disorder patients, the duration of treatment (three months compared to six months) had no effect on the ability of patients to taper to zero dose.

six months) had no effect on the ability of patients to taper to zero dose. Solurizes attributable to alprazolam tablets were seen after drug discontinuance or dose reduction in 8 of 1980 patients with panic disorder or in patients participating in clinical trials where doses of alprazolam tablets greater than 4 mg/day for over 3 months were permitted. Five of these cases clearly occurred during abrupt dose reduction, or discontinuation from daily doses of 2 to 10 mg. Three cases occurred in situations where there was not a clear relationship to abrupt dose reduction or discontinuation. In one instance, seizure occurred after discontinuation from a single dose of 1 mg after tapering at a rate of 1 mg every three days from 6 mg daily. In two other instances, the relationship to these is indetermined to indet the tapering at a rate of 1 mg after. eterminate; in both of these cases the patients had been receiving doses of 3 mg daily price taper is indeterminate; in both of these cases the patients had been receiving doses of 3 mg daily prior to seizure. The duration of use in the above 8 cases ranged from 4 to 22 weeks. There have been occasional voluntary reports of patients developing seizures while apparently tapering gradually from alprazolam tablets. The risk of seizure seems to be greatest 24-72 hours after discontinuation (see DOSAGE AND ADMINISTRATION for recommended tapering and discontinuation schedule).

Status enilenticus and its treatment:

dical event voluntary reporting system shows that withdrawal seizures have been reported in ion with the discontinuation of alorazolam tablets. In most cases, only a single seizure was The metucal event voluntary reporting system shows that withinkava secures have been reported in association with the discontinuation of algrazolan tablets. In most cases, only a single seizure was reported; however, multiple seizures and status epilepticus were reported as well. Ordinarily, the treatment of status epilepticus of any etiology involves use of intravenous benzoatazizeptines plus phenytoin or barbiturates, maintenance of a patent airway and adequate hydration. For additional details regarding therapy, consultation with an appropriate specialist may be considered

registring unergy, constrained must an approximate opportunity opp ses of alprazolam situations, it is recommended that the same total daily dose be given divided as more frequent administrations (see DOSAGE AND ADMINISTRATION).

auministrations, lete boond and administration, Tisk of dose reduction: Withdrawal reactions may occur when dosage reduction occurs for any reason. This includes purposeful tapering, but also inadvertent reduction of dose (e.g., the patient forgets, the patient is admitted to a hospital, etc.). Therefore, the dosage of alprazolam tablets should be reduced or discontinued gradually (see DOSAGE AND ADMINISTRATION).

Alprazolam tablets are not of value in the treatment of psychotic patients and should not be employed Appraction tables are not or value in the treatment of psychology patients and should not be employed in lieu of appropriate treatment for psycholsis. Because of its CNS depressant effects, patients receiving alprazolam tablets should be cautilined against engaging in hazardous occupations or activities requiring complete mental alertness such as operating machinery or driving a motor which. For the same reason, patients should be cautioned about the simultaneous ingestion of alcohol and other CNS depressant drugs during treatment with alprazolam tablets.

Benzodiazepines can potentially cause fetal harm when administered to pregnant women. If alprazolam tablets are used during pregnancy, or if the patient becomes pregnant while aking this drug, the patient should be apprised of the potential hazard to the fetus. Because of experience with other members of should be apprised of the potential hazard to the fetus. Because of experience with other members of the benzodiazepine class, alprazolam tablets are assumed to be capable of causing an increased risk of congenital abnormalities when administered to a pregnant woman during the first trimester. Because use of these drugs is rarely a matter of urgency, their use during the first trimester should almost always be avoided. The possibility that a woman of childbearing potential may be pregnant at the time of institution of therapy should be considered. Patients should be advised that if they become pregnant during therapy or intend to become pregnant they should communicate with their physicians about the desirability of discontinuing the drug.

Alprazolam interaction with drugs that inhibit metabolism via cvtochrome P450 3A

Alprazolam interaction with drugs that inhibit metabolism via cytochrome P450 3A: The initial step in alprazolam metabolism is hydroxylation catalyzed by cytochrome P450 3A (CYP 3A). Drugs that inhibit this metabolic pathway may have a profound effect on the clearance of alprazolam. Consequently, alprazolam should be avoided in patients receiving very potent inhibitors of CYP 3A. With drugs inhibiting CYP 3A to a lesser but still significant degree, alprazolam should be used only with caution and consideration of appropriate dosage reduction. For some drugs, an interaction with alprazolam has been quantified with clinical data; for other drugs, interactions are predicted from *in vitro* data and/or experience with similar drugs in the same pharmacologic class.

The following are examples of drugs known to inhibit the metabolism of alprazolam and/or related benzodiazepines, presumably through inhibition of CYP 3A.

Denzoolażepines, presumably through inhibition of CYP 3A. Potent CYP 3A inhibitors: Azole antifungal agents--Although *in vivo* interaction data with alprazolam are not available, ketoconazole and itraconazole are potent CYP 3A inhibitors and the coadministration of alprazolam with them is not recommended. Other azole-type antifungal agents should also be considered potent CYP 3A inhibitors and the coadministration of alprazolam with them is not recommended (see CONTRAINDICATIONS).

Drugs demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving alprazo

Engly countil and the two of appropriate approximations to not water or unitable stocks meaning (caution and consideration of appropriate approximate approximations) and the recommen coadministration with the following drugs): Netazodone — Coadministration of netazodone increased alprazolam concentration two-fold

Fluxoxamine—Coadministration of fluxoxamine approximately doubled the maximum plasma concentration of alprazolam, decreased clearance by 49%, increased hall-life by 71%, and decreased measured psychomotor performance.

Cimetidine—Coadministration of cimetidine increased the maximum plasma concentration of alprazolam by 86%, decreased clearance by 42%, and increased half-life by 16%.

Other drugs possibly affecting alprazolam metabolism: Other drugs possibly affecting alprazolam metabolism by inhibition of CYP 3A are discussed in the PRECAUTIONS section (see PRECAUTIONS-Drug Interactions). PRECAUTIONS

General: If alprazolam tablets are to be combined with other psychotropic agents or anticonvulsant drugs, careful consideration should be given to the pharmacology of the agents to be employed, particularly with compounds which might potentiate the action of benzodiazepines (see **Drug Interactions**).

As with other psychotropic medications, the usual precautions with respect to administration of the drug and size of the prescription are indicated for severely depressed patients or those in whom there is reason to expect concealed suicidal ideation or plans.

reason to expect concealed suicidal ideation or plans. It is recommended that the dosage be limited to the smallest effective dose to preclude the develop of ataxia or oversedation which may be a particular problem in elderly or debilitated patients DOSAGE AND ADMINISTRATION). The usual precautions in treating patients with impaired r hepatic or pulmonary function should be observed. There have been are reports of death in pat with severe pulmonary disease shortly after the initiation of treatment with alprazolam table

ecreased systemic alprazolam elimination rate (e.g., increased plasma half-life) has been observed in oth alcoholic liver disease patients and obese patients receiving alprazolam tablets (see CLINICAL PHARMACOLOGY)

Episodes of hypomania and mania have been reported in association with the use of alprazolam tablets in patients with depression.

Alprazolam has a weak uricosuric effect. Although other medications with weak uricosuric effect have been reported to cause acute renal failure, there have been no reported instances of acute renal failure attributable to therapy with alprazolam tablets.

Information for Patients: For all users of alprazolam tablets: To assure safe and effective use of benzodiazepines, all patients prescribed alprazolam tablets should be provided with the following guidance. In addition, panic disorder patients, for whom doses greater than 4 mg/day are typically prescribed, should be advised about the risks associated with the use of higher doses

Inform your physician about any alcohol consumption and medicine you are taking now including readication you may buy without a prescription. Alcohol should generally not be used during treatment with benzodiazepines.

- Not recommended for use in pregnancy. Therefore, inform your physician if you are pregnant, if you are planning to have a child, or if you become pregnant while you are taking this medication.

are planning to have a child, or if you become pregnant while you are taking this medication.
3. Inform you physician if you are nursing.
4. Until you experience how this medication affects you, do not drive a car or operate potentially dangerous machinery, etc.
5. Do not increase the dose even if you think the medication "does not work anymore" without consulting your physician. Benzodiazepines, even when used as recommended, may produce emotional and/or physical dependence.
6. Do not strong taking this medication abruptly or decrease the dose without consulting your physician, since withdrawal symptoms can occur.

Additional advice for panic disorder patients: The use of alprazolam tablets at doses greater than 4 mg/day, often necessary to treat panic disorder, is accompanied by risks that you need to carefully consider. When used at doses greater than 4 mg/day, which may or may not be required for your treatment, alprazolam tablets have the potential to cause severe emotional and physical dependence in some patients and these patients may find it exceedingly difficult to terminate treatment. In two controlled trials of six to eight weeks duration where the ability of patients to discontinue medication was measured, 7 to 29% of patients treated with alprazolam tablets did not completely taper off therapy. In a controlled postmarketing discontinuation study of panic disorder patients, the patients treated with doses of alprazolam tablets greater than 4 mg/day have more difficulty tapering to zero dose than patients treated with less than 4 mg/day, In all cases, it is important that your physician helps you discontinue this medication in a careful and safe manner to avoid overly extended use of alprazolam tablets. Additional advice for panic disorder patients:

In addition, the extended use at doses greater than 4 mg/day appears to increase the incidence and severity of withdrawal reactions when alprazolam tablets are discontinued. These are generally minor but seizure can occur, especially if you reduce the dose too rapidly or discontinue the medication abruptly. Seizure can be life-threatening.

Laboratory Tests:

Laboratory tests are not ordinarily required in otherwise healthy patients.

Drug Interactions The benzodiazepin rrug interactions: he benzodiazepines, including alprazolam, produce additive CNS depressant effects dministered with other psychotropic medications, anticonvulsants, antihistaminics, ethanol rugs which themselves produce CNS depression.

The steady state plasma concentrations of imipramine and desipramine have been reported to be increased an average of 31% and 20%, respectively, by the concomitant administration of alprazolam tablets in doses up to 4 mg/day. The clinical significance of these changes is unknown.

tablets in doses up to 4 mg/day. The clinical significance of these changes is unknown. Drugs that inhibit algrazolam metabolism via cyclochrome P450 34. The initial step in algrazolam metabolism is hydroxylation catalyzed by cytochrome P450 3A (CYP 3A). Drugs which inhibit this metabolic pathway may have a protonul diffect on the clearance of algrazolam (see CONTRINDICATIONS and WARNINGS for additional drugs of this type). Drugs demonstrated to be CYP 3A inhibitors of possible clinical significance on the basis of clinical studies involving algrazolam (caution is recommended during coadministration with algrazolam): Fluoxetine—Coadministration of fluoxetine with algrazolam increased the maximum plasma concentration of algrazolam by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.

Propoxyphene—Coadministration of propoxyphene decreased the maximum plasma concentration of alprazolam by 6%, decreased clearance by 38%, and increased half-life by 58%.

Oral Contraceptives—Coadministration of oral contraceptives increased the maximum concentration of alprazolam by 18%, decreased clearance by 22%, and increased half-life by 25

Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam

a prazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice. Data from *in vitro* studies of alprazolam suggest a possible drug interaction with alprazolam for the following: sertraline ado parxetine. However, data from an *in vivo* drug interaction study involving a single dose of alprazolam 1 mg and steady state doses of sertraline (30 to 150 mg/day) did not reveal any clinically significant changes in the pharmacokinetics of alprazolam. Data from *in vitro* studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: regotamine, cyclosporine, aminderone, nicardipine, and nifetpine. Caution is recommended during the coadministration of any of these with alprazolam (see **WARNINGS**).

Drug/Laboratory Test Interactions:

Although interactions between benzodiazepines and commonly employed clinical laboratory tests have occasionally been reported, there is no consistent pattern for a specific drug or specific test.

Carcinogenesis, Mutagenesis, Impairment of Fertility: No evidence of carcinogenic potential was observed during 2-year bioassay studies of alprazolam in rats at doses up to 30 mg/kg/day (150 times the maximum recommended daily human dose of 10 mg/day) and in mice at doses up to 10 mg/kg/day (50 times the maximum recommended daily human dose). Alprazolam was not mutagenic in the rat micronucleus test at doses up to 100 mg/kg, which is 500 times the maximum recommended daily human dose of 10 mg/kg. Alprazolam also was not mutagenic in vitro in the DNA Damage/Alkaline Elution Assay or the Ames Assay.

Alprazolam produced no impairment of fertility in rats at doses up to 5 mg/kg/day, which is 25 times the maximum recommended daily human dose of 10 mg/day.

Pregnancy: Teratogenic Effects: Pregnancy Category D: (see WARNINGS section).

Nonteratogenic Effects: It should be considered that the child born of a mother who is receiving benzodiazepines may be at some risk for withdrawal symptoms from the drug during the postnatal period. Also, neonatal flaccidity and respiratory problems have been reported in children born of mothers who have been receiving benzodiazepines.

Labor and Delivery: Alprazolam tablets have no established use in labor or delivery.

Nursing Mothers:

azepines are known to be excreted in human milk. It should be assumed that alprazolam is as pericultarappine's alle whom to be executed in minama time, it shollow be assumined unar applicabilities as well. Chronic administration of diazepart to unarising mothers has been reported to cause their infants to become lethargic and to lose weight. As a general rule, nursing should not be undertaken by mothers who must use alprazolam tablets.

ADVERSE REACTIONS

Pediatric Use: Safety and effectiveness of alprazolam tablets in individuals below 18 years of age have not been

Side effects to alprazolam tablets, if they occur, are generally observed at the beginning of therapy and usually disappear upon continued medication. In the usual patient, the most frequent side effects are likely to be an extension of the pharmacological activity of alprazolam, e.g., drowsiness or light-

The data cited in the two tables below are estimates of untoward clinical event incidence among patients who participated under the following clinical conditions: relatively short duration (i.e., four weeks) placebo-controlled clinical studies with dosages up to 4 mg/day of alprazolam tablets (for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety) and short-term (up to ten weeks) placebo-controlled clinical studies with dosages up to 10 mg/day of alprazolam tablets in patients with panic disorder, with or without agoraphobia.

These data cannot be used to predict precisely the incidence of untoward events in the course of usual medical practice where patient characteristics, and other factors often differ from those in clinical trials. These figures cannot be compared with those obtained from other clinical studies involving related drug products and placebo as each group of drug trials are conducted under a different set of conditions.

Comparison of the cited figures, however, can provide the prescriber with some basis for estimating the

reliative contributions of drug and non-drug factors to the untoward event incidence in the population studied. Even this use must be approached cautiously, as a drug may relieve a symptom in one patient but induce it in others. (For example, an anxiolytic drug may relieve dry mouth [a symptom of anxiety] in some subjects but induce it [an untoward event] in others.)

Geriatric Use: Geriatric Use: The elderly may be more sensitive to the effects of benzodiazepines. They exhibit higher plasma alprazolam concentrations due to reduced clearance of the drug as compared with a younger population receiving the same doses. The smallest effective dose of alprazolam tablets should be used in the elderly to preclude the development of ataxia and oversedation (see CLINICAL PHARMACOLOGY and DOSAGE AND ADMINISTRATION).

headedness.

Additionally, for anxiety disorders the cited figures can provide the prescriber with an indication as to the frequency with which physician intervention (e.g., increased surveillance, decreased dosage or discontinuation of drug therapy) may be necessary because of the untoward clinical event.

	ANXIETY DISORDE	RS	
	Treatment-En Symptom Inci	idence [†]	Incidence of Intervention Because of Symptom ALPRAZOLAM TABLETS
Number of Patients	ALPRAZOLAM TABLETS 565	505	565
% of Patients Reporting:	505	505	505
Central Nervous System Drowsiness Light-headedness Depression Headache Confusion Insomnia Nervousness Syncope Dizziness Akathisia Tiredness/Sleepiness <u>Gastrointestinal</u> Dry Mouth Constipation	41.0 20.8 13.9 12.9 9.9 4.1 3.1 1.8 1.6 • •	21.6 19.3 18.1 19.6 10.0 18.4 10.3 4.0 0.8 1.2 *	15.1 1.2 2.4 1.1 0.9 1.3 1.1 • 2.5 • 1.8 0.7 0.9
Diarrhea Nausea/Vomiting Increased Salivation	10.1 9.6 4.2	10.3 12.8 2.4	1.2 1.7 *
Cardiovascular Tachycardia/Palpitations Hypotension	7.7 4.7	15.6 2.2	0.4
Sensory Blurred Vision	6.2	6.2	0.4
Musculoskeletal Rigidity Tremor	4.2 4.0	5.3 8.8	* 0.4
Cutaneous Dermatitis/Allergy	3.8	3.1	0.6
Other Nasal Congestion Weight Gain Weight Loss * None reported	7.3 2.7 2.3	9.3 2.7 3.0	• •

+ Events reported by 1% or more of alprazolam tablet patients are included.

۲

In addition to the relatively common (i.e., greater than 1%) untoward events enumerated in the table above, the following adverse events have been reported in association with the use of benzodiazepines: dystornia, irritability, concentration difficulties, anorexia, transient amnesia or memory impairment, loss of coordination, fatigue, esizures, sedation, silured speech, jaundice, musculoskeltal weakness, pruritus, diplopia, dysarthria, changes in libido, menstrual irregularities, incontinence and urinary retorion

P	ANIC DISORDERS	
		nt-Emergent
	ALPRAZOLAM TABLET	S PLACEBO
Number of Patients	1388	1231
% of Patients Reporting:		
Central Nervous System	76.8	42.7
Drowsiness Fatigue and Tiredness	48.6	42.7
Impaired Coordination	40.0	17.9
Irritability	33.1	30.1
Memory Impairment	33.1	22.1
Light-headedness/Dizziness	29.8	36.9
Insomnia Headache	29.4 29.2	41.8 35.6
Cognitive Disorder	29.2	20.5
Dysarthria	23.3	6.3
Anxiety	16.6	24.9
Abnormal Involuntary Movement	14.8	21.0
Decreased Libido	14.4	8.0
Depression	13.8	14.0
Confusional State Muscular Twitching	10.4 7.9	8.2 11.8
Increased Libido	7.7	4.1
Change in Libido (Not Specified)	7.1	5.6
Weakness	7.1	8.4
Muscle Tone Disorders	6.3	7.5
Syncope	3.8	4.8
Akathisia Agitation	3.0 2.9	4.3 2.6
Disinhibition	2.5	1.5
Paresthesia	2.4	3.2
Talkativeness	2.2	1.0
Vasomotor Disturbances	2.0	2.6
Derealization	1.9	1.2
Dream Abnormalities Fear	1.8	1.5
Feeling Warm	1.4 1.3	1.0 0.5
Gastrointestinal		
Decreased Salivation	32.8	34.2
Constipation	26.2	15.4
Nausea/Vomiting	22.0	31.8
Diarrhea	20.6	22.8
Abdominal Distress Increased Salivation	18.3 5.6	21.5 4.4
	5.6	4.4
Cardio-Respiratory Nasal Congestion	17.4	16.5
Tachycardia	15.4	26.8
Chest Pain	10.6	18.1
Hyperventilation	9.7	14.5
Upper Respiratory Infection	4.3	3.7
Sensory		
Blurred Vision Tinnitus	21.0	21.4 10.4
	6.6	10.4
Musculoskeletal		
Muscular Cramps Muscle Stiffness	2.4 2.2	2.4 3.3
	2.2	0.0
Cutaneous Sweating	15.1	23.5
Rash	10.8	8.1
Other	10.0	0.1
Increased Appetite	32.7	22.8
Decreased Appetite	27.8	24.1
Weight Gain	27.2	17.9
Weight Loss	22.6	16.5
Micturition Difficulties	12.2	8.6
Menstrual Disorders Sexual Dysfunction	10.4 7.4	8.7 3.7
Edema	4.9	5.6
Incontinence	1.5	0.6
Infection	1.3	1.7

rted by 1% or more of alprazolam tablet patie

In addition to the relatively common (i.e., greater than 1%) untoward events enumerated in the table above, the following adverse events have been reported in association with the use of alprazolam tablets: seizures, hallucinations, depersonalization, taste alterations, diplopia, elevated bilirubin, elevated hepatic enzymes, and jaundice.

There have also been reports of withdrawal seizures upon rapid decrease or abrupt discontinuation of alprazolam tablets (see WARNINGS).

To discontinue treatment in patients taking alprazolam tablets, the dosage should be reduced slo keeping with good medical practice. It is suggested that the daily dosage of alprazolam table

decreased by no more than 0.5 mg every three days (see **DOSAGE AND ADMINISTRATION**). Some patients may benefit from an even slower dosage reduction. In a controlled postmarketing discontinuation study of panic disorder patients which compared this recommended taper schedule, no a slower taper schedule, no difference was observed between the groups in the proportion of patients who tapered to zero dose; however, the slower schedule was associated with a reduction in symptoms consolided with a universema transformation difference was associated with a reduction in symptoms consolided with a universema transformation difference was associated with a reduction in symptoms consolided with a universema schedule universe. associated with a withdrawal syndrome.

۲

Panic disorder has been associated with primary and secondary major depressive disorders and increased reports of suicide among untreated patients. Therefore, the same precaution must be exercised when using doses of alprazolam tablets greater than 4 mg/day in treating patients with panic disorders as is exercised with the use of any psychotropic drug in treating depressed patients or those in whom there is reason to expect concealed suicidal ideation or plans.

in whom there is reason to expect concealed suicidal ideation or plans. As with all benzodiazepines, paradoxical reactions such as stimulation, increased muscle spasticity, sleep disturbances, hallucinations and other adverse behavioral effects such as agitation, rage, irritability, and aggressive or hostile behavior have been reported rarely. In many of the spontaneous case reports of adverse behavioral effects, patients were receiving other CNS drugs concomitantly and/or were described as having underlying psychiatric conditions. Should any of the above events occur, alprazolam should be discontinued. Isolated published reports involving small numbers of patients have suggested that patients who have borderline personality disorder, a prior history of violent or aggressive behavior, or alcohol or substance abuse may be at risk for such events. Instances of irritability, hostility, and intrusive thoughts have been reported during discontinuation of alprazolam in patients have brave disconter.

patients with peak number allocations and a patients participating in the clinical program for alprazolam tablets. The following incidences of abnormalities shown below were observed in patients receiving alprazolam tablets and in patients in the corresponding placebo group. Few of these abnormalities were considered to be of physiological significance.

.,	ALPRAZOLAM TABLETS		PLACEBO	
	Low	High	Low	High
Hematology				
Hematocrit	*	*	*	*
Hemoglobin	*	*	*	*
Total WBC Count	1.4	2.3	1.0	2.0
Neutrophil Count	2.3	3.0	4.2	1.7
Lymphocyte Count	5.5	7.4	5.4	9.5
Monocyte Count	5.3	2.8	6.4	*
Eosinophil Count	3.2	9.5	3.3	7.2
Basophil Count	*	*	*	*
Urinalysis				
Albumin	-	*	-	*
Sugar	-	*	_	*
RBC/HPF	-	3.4	-	5.0
WBC/HPF	-	25.7	-	25.9
Blood Chemistry				
Creatinine	2.2	1.9	3.5	1.0
Bilirubin	*	1.6	*	*
SGOT	*	3.2	1.0	1.8
Alkaline Phosphatase	*	1.7	*	1.8

* Less than 1%

When treatment with alprazolam tablets is protracted, periodic blood counts, urinalysis and blood chemistry analyses are advisable.

Minor changes in EEG patterns, usually low-voltage fast activity have been observed in patients during therapy with alprazolam tablets and are of no known significance

Therapy with alprazolam tablets and are of no known significance. Post Introduction Reports: Various adverse drug reactions have been reported in association with the use of alprazolam tablets since market introduction. The majority of these reactions were reported through the medical event voluntary reporting system. Because of the spontaneous nature of the reporting of medical events and the lack of controls, a causal relationship to the use of alprazolam tablets cannot be readily determined. Reported events include: liver enzyme elevations, hepatitis, hepatic failure, Stevens-Johnson syndrome, hyperprolactinemia, gynecomastia and galactorrhea.

DRUG ABUSE AND DEPENDENCE

DRUG ABUSE AND DEPENDENCE Physical and Psychological Dependence: Withdrawal symptoms similar in character to those noted with sedative/hypnotics and alcohol have occurred following discontinuance of benzodiazepines, including alprazolam tables. The symptoms can range from mild dysphoria and insomia to a major syndrome that may include abdominal and muscle cramps, vomiting, sweating, tremors and convulsions. Distinguishing between withdrawal emergent signs and symptoms and the recurrence of liness is often difficult in patients undergoing dose reduction. The long term strategy for treatment of these phenomena will vary with their cause and the therapeutic goal. When necessary, immediate management of withdrawal symptoms. There have been reports of failure of other benzodiazepines to fully suppress these withdrawal symptoms. There have been reports of failtubed to incomplete cross-tolerance but may also reflect the use of an inadequate dosing regimen of the substituted benzodiazepine or the effects of concomitant medications.

or the substituted benzoalazepine or the effects of concontraint medications. While it is difficult to distinguish withdrawal and recurrence for certain patients, the time course and the nature of the symptoms may be helpful. A withdrawal syndrome typically includes the occurrence of new symptoms, tends to appear toward the end of taper or shortly after discontinuation, and will decrease with time. In recurring panic disorder, symptoms similar to those observed before treatment may recur either early or late, and they will persist.

While the severity and incidence of withdrawal phenomena appear to be related to dose and duration of Write the seventy and incidence of withdrawal prenomena appear to be related to dose and oursarour treatment, withdrawal symptoms, including seizures, have been reported after only brief therapy with alprazolam tablets at doses within the recommender ange for the treatment of anxiety (e.g., 0.75 to 4 mg/day). Signs and symptoms of withdrawal are often more prominent lafter napid decrease of dosage or abrupt discontinuance. The risk of withdrawal seizures may be increased at doses above 4 mg/day (see WARMNGS).

Patients, especially individuals with a history of seizures or epilepsy, should not be abruptly discontinued from any CNS depressant agent, including alprazolam tablets. It is recommended that all patients on alprazolam tablets who require a dosage reduction be gradually tapered under close supervision (see WARNINGS and DOSAGE AND ADMINISTRATION).

WARNINGS and DOSAGE AND ADMINIS HATION). Psychological dependence is a risk with all benzodiazepines, including alprazolam tablets. The risk of psychological dependence may also be increased at doses greater than 4 mg/day and with longer term use, and this risk is further increased in patients with a history of alcohol or drug abuse. Some patients have experienced considerable difficulty in tapering and discontinuing from alprazolam tablets, especially those receiving higher doses for extended periods. Addiction-prone individuals should be under careful surveiliance when receiving alprazolam tablets. As with all anxiolytics, repeat prescriptions should be limited to those who are under medical supervision.

Controlled Substance Class:

Administration and alprazolam tablets have been assigned to Schedule IV. OVERDOSAGE

of alprazolam overdosage include sompolence confusion impaired coordination Mamiestations of approximal overdosage include sommolence, contusion, impaired coordination, diminished reflexes and come. Death has been reported in association with overdoses of alprazolam by itself, as it has with other benzodiazepines. In addition, fatalities have been reported in patients who have overdosed with a combination of a single benzodiazepine, including alprazolam, and alcohol; alcohol levels seen in some of these patients have been lower than those usually associated with alcohol-induced fatality.

The acute oral LD₂₀ in rats is 331-2171 mg/kg. Other experiments in animals have indicated that cardiopulmonary collapse can occur following massive intravenous doses of alprazolam (over 195 mg/kg; 975 times the maximum recommended daily human dose of 10 mg/day). Animals could be resuscitated with positive mechanical ventilation and the intravenous influsion of norepinephrine bitartrate

Animal experiments have suggested that forced diuresis or hemodialysis are probably of little value in treating overdosage.

General Treatment of Overdose:

Overdosage reports with alprazolam tablets are limited. As in all cases of drug overdosage, respiration Overtoosage reports with aptraction tablets are imited. As in an cases of orug overtoosage, respiration, pulse rate, and blood pressure should be monitored. General supportive measures should be employed, along with immediate gastric lavage. Intravenous fluids should be administered and an adequate airway maintained. If hypotension occurs, it may be combaded by the use of vasopressors. Dialysis is of limited value. As with the management of intentional overdosing with any drug, it should be borne in mind that multiple agents may have been ingested.

multiple agents may have been ingested. Flumazenii, a specific benzodiazepine receptor antagonist, is indicated for the complete or partial reversal of the sedative effects of benzodiazepines and may be used in situations when an overdose with a benzodiazepine is known or suspected. Prior to the administration of flumazenii, necessary measures should be instituted to secure airway, ventilation and intravenous access. Flumazenii is intended as an adjunct to, not as a substitute for, proper management of benzodiazepine verdose. Patients treated with flumazenii should be monitored for re-sedation, respiratory depression, and other residual benzodiazepine effects for an appropriate period after treatment. The presentiber should be aware of a risk of seizure in association with flumazenii treatment, particularly in long-term benzodiazepine users and in cyclic antifareasent provides provides flumazenii necknosii meast including users and in cyclic antidepressant overdose. The complete flumazenil package insert including CONTRAINDICATIONS, WARNINGS and PRECAUTIONS should be consulted prior to use. DOSAGE AND ADMINISTRATION

Dosage should be individualized for maximum beneficial effect. While the usual daily dosages gi below will meet the needs of most patients, there will be some who require doses greater than 4 mg/c In such cases, dosage should be increased cauliously to avoid adverse effects.

Anxiety disorders and transient symptoms of anxiety: Treatment for patients with anxiety should be initiated with a dose of 0.25 to 0.5 mg given three times daily. The dose may be increased to achieve a maximum therapeutic effect, at intervals of 3 to 4 days

to a maximum daily dose of 4 mg, given in divided doses. The lowest possible effective dose should be employed and the need for continued treatment reassessed frequently. The risk of dependence may increase with dose and duration of treatment.

In elderly patients, in patients with advanced liver disease or in patients with debilitating disease, the usual starting dose is 0.25 mg, given two or three times daily. This may be gradually increased if needed and tolerated. The elderly may be especially sensitive to the effects of benzodiazepines.

If side effects occur at the recommended starting dose, the dose may be lowered.

In all patients, dosage should be reduced gradually when discontinuing therapy or when decreasing the daily dosage. Although there are no systematically collected data to support a specific discontinuation schedule, it is suggested that the daily dosage be decreased by no more than 0.5 mg every three days. Some patients may require an even slower dosage reduction.

Some patients may require an even server server server and the use of alprazolam labels at doses greater than 4 mg daily. In controlled trials conducted to establish the efficacy of alprazolam tablets in patient is closered, coses in the range of 1 to 10 mg daily were used. The mean dosage employed was approximately 5 to 6 mg daily. Among the approximately 1700 patients participating in the panic disorder development program, about 300 received alprazolam tablets in dasage of greater than 7 mg/day, including approximately 100 patients who received maximum dosages of greater than 9 mg/day. Occasional patients required as much as 10 mg day to achieve a successful response.

Generally, therapy should be initiated at a low dose to minimize the risk of adverse responses in patients especially sensitive to the drug. Thereafter, the dose can be increased at intervals equal to at least 5 times the elimination half-life (about 11 hours in young patients, about 16 hours in elderly patients). Longer titration intervals should probably be used because the maximum therapeutic response may not cocur until after the plasma levels achieve steady state. Dose should be advanced until an acceptable therapeutic response (i.e., a substantial reduction in or total elimination of panic attacks) is achieved, intolerance occurs, or the maximum recommended dose is attained. For patients receiving doses greater than 4 mg/day, periodic reassessment and consideration of dosage reduction is advised. In a controlled postmarketing dose-response study, patients treated with doses of alpracalam tablets greater than 4 mg/day for three months were able to taper to 50% of their total maintenance dose without apparent loss of clinical benefit. Because of the danger of withdrawai, abrupt discontinuation of treatment should be avoided (see **WARNINGS, PRECAUTIONS, DRUG ABUSE AND DEPENDENCE**). The following reminers in that follows the roticitine advise:

treatment should be avoided (see WARNINGS, PHECAUTIONS, DHUG ABUSE AND DEPENDENCE). The following regiment is one that follows the principles outlined above: Treatment may be initiated with a dose of 0.5 mg three times daily. Depending on the response, the dose may be increased at intervals of 3 to 4 days in increments of no more than 1 mg per day. Slower titration to the dose levels greater than 4 mg/day may be advisable to allow full expression of the pharmacodynamic effect of alprazolam tables. To lessen the possibility of interdose symptoms, the times of administration should be distributed as evenly as possibility of interdose symptoms, that is, on a three or four times per day schedule.

The necessary duration of treatment for panic disorder patients responding to alprazolam tablets is The neccodary concerned in detantion for panel operations operating operating approximation approxim

without recurrence of symptoms and/or the manifestation of withdrawal phenomena. In any case, reduction of dose must be undertaken under close supervision and must be gradual. If significant withdrawal symptoms develop, the previous dosing schedule should be reinstituted and, only after stabilization, should a less rapid schedule of discontinuation be attempted. In a controlled postmarketing discontinuation study of panic disorder patients which compared this recommended taper schedule with a slower taper schedule, no difference was observed between the groups in the proportion of patients who teapered to zero dose; however, the slower schedule was associated with a reduction in symptoms associated with a withdrawal syndrome. It is suggested that the dose be reduced by no more than 0.5 mg every three days, with the understanding that some patients may benefit from an even more gradual discontinuation. Some patients may benefit from an even more gradual discontinuation.

HOW SUPPLIED lote LISP are available as:

0.25 mg White, oval, debosed "2087" over "V" on one side and scored on the reverse side, in bottles of 10, 30, 60, 90, 100, 120, 500 and 1000.

0.5 mg: Peach, oval, debossed "2088" over "V" on one side and scored on the reverse side, in bottles of 10, 30, 60, 90, 100, 120, 500 and 1000.

1 mg: Blue, oval, debossed "2089" over "V" on one side and scored on the reverse side, in bottles of 10, 30, 60, 90, 100, 120, 500 and 1000.

2 mg: White, oblong, multi-scored, beveled edged, debossed "2090" on one side and debossed "V" on the reverse side, in bottles of 10, 90, 100, 500 and 1000.

Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Keep container tightly closed.

Dispense in tight, light-resistant container

ANIMAL STUDIES

ANIMAL STUDIES When rats were treated with alprazolam at 3, 10, and 30 mg/kg/day (15 to 150 times the maximum recommended human dose) orally for 2 years, a tendency for a dose related increase in the number of cataracts was observed in females and a tendency for a dose related increase in corneal vascularization was observed in males. These lesions did not appear until after 11 months of treatment.

CLINICAL STUDIES

Alprazolam tablets were compared to placebo in double blind clinical studies (doses up to 4 mg/day) in Application tables were compared to placebol models und clinical studies (closes up to 4 ingrady) in patients with a diagnosis of a nixely or anxiety with associated depressive symptomatology. Alprazolam tablets were significantly better than placebo at each of the evaluation periods of these four week studies as judged by the following psychometric instruments: Physician's Global Impressions, Hamilton Anxiety Rating Scale, Target Symptoms, Patient's Global Impressions and Self-Rating Symptom Scale. Panic Disorder

Support for the effectiveness of alprazolam tablets in the treatment of panic disorder came from three short-term, placebo-controlled studies (up to 10 weeks) in patients with diagnoses closely corresponding to DSM-III-R criteria for panic disorder.

corresponding to DSM-III-R criteria for panic disorder. The average dose of alprazolam tablets was 5-6 mg/day in two of the studies, and the doses of alprazolam tablets were fixed at 2 and 6 mg/day in the third study. In all three studies, alprazolam tablets were superior to placebo on a variable defined as "the number of patients with zero panic attacks" (range, 37-83% met this criterion), as well as on a global improvement score. In two of the three studies, alprazolam tablets were superior to placebo on a variable defined as "change from baseline on the number of panic attacks per week" (range, 3.3-5.2), and also on a phobia rating scale. A subgroup of patients who were improved on alprazolam tablets during short-term treatment in one of these trials was continued on an open basis up to eight months, without apparent loss of benefit.

Manufactured for: QUALITEST PHARMACEUTICALS Huntsville, AL 35811

8182238 Rev 12/09 R2





